 Home > Active Ingredient News > Antitumor Therapy > JCO: Phase 3 clinical trial | gemcitabine + cisplatin combined with bevacizumab for the treatment of advanced urothelial carcinoma

JCO: Phase 3 clinical trial | gemcitabine + cisplatin combined with bevacizumab for the treatment of advanced urothelial carcinoma

 Last Update: 2021-05-21
 Source: Internet
 Author: User

Tags

immune system development

marco group

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Since the first immune checkpoint inhibitor application and clinical approval in 2016, the treatment of metastatic urothelial cell (transitional cell) carcinoma has undergone major changes; since then, 7 new drugs have been approved for the treatment of metastasis Sexual urothelial carcinoma.

The dual chemotherapy regimen of immune gemcitabine and cisplatin (GC) has also become the standard treatment for metastatic urothelial cancer

Based on the role of angiogenesis in the growth and development of urothelial cancer, Rosenberg et al.

Blood vessel

From July 2009 to December 2014, a total of 506 patients with metastatic urothelial cancer who had not received chemotherapy for metastatic lesions and had not received neoadjuvant or adjuvant chemotherapy within 12 months were randomly assigned to GCB Group or GCP group.

A: overall survival; B: progression-free survival

The median follow-up was 76.

Hematological Adverse Reaction

Two no significant difference in the proportion of patients with grade 3 or more adverse events in the two treatment arms , while increasing the number of occurrences in the bevacizumab group bevacizumab-related toxicity (e.

There was no significant difference in the proportion of patients with grade 3 or above adverse events in each treatment arm

In summary, adding bevacizumab to the GC regimen cannot improve the overall survival of patients with metastatic urothelial cancer .

Adding bevacizumab to the GC regimen does not improve the overall survival of patients with metastatic urothelial cancer .

Original source:

Jonathan E.

org/doi/full/10.
1200/JCO.
21.
00286" target="_blank" rel="noopener">Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance) in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

High Quality Resveratrol 99% powder 501-36-0 Shaanxi Dideu Medichem Co.Ltd

CAS No.: 501-36-0

Chemical Grade

$1/KG FOB

High purity Epirubicin hydrochloride 98% with best price 56390-09-1 and Epirubicin hydrochloride raw powder

CAS No.: 56390-09-1

Pharmacy Grade

$8.8-10/MT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.